Geode Capital Management LLC Increases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Geode Capital Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,060,131 shares of the biopharmaceutical company’s stock after buying an additional 30,901 shares during the quarter. Geode Capital Management LLC’s holdings in Halozyme Therapeutics were worth $175,194,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its position in shares of Halozyme Therapeutics by 15.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,771 shares of the biopharmaceutical company’s stock valued at $616,000 after acquiring an additional 1,554 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Halozyme Therapeutics by 21.3% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 11,467 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 2,016 shares during the period. Raymond James & Associates grew its holdings in Halozyme Therapeutics by 51.8% during the 2nd quarter. Raymond James & Associates now owns 146,261 shares of the biopharmaceutical company’s stock valued at $7,658,000 after buying an additional 49,923 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 261 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth $225,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HALO shares. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler lifted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,778,084.68. This represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 40,000 shares of company stock worth $2,242,100. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $48.00 on Monday. The firm has a market capitalization of $6.11 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 0.43 and a beta of 1.23. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business has a 50 day simple moving average of $51.43 and a 200-day simple moving average of $54.07. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.